The recent partnership between Somite Therapeutics and OmniaBio Inc. marks a promising leap forward in treating Duchenne muscular dystrophy (DMD). Combining Somite's AI-driven approach with OmniaBio's cell and gene therapy expertise, this collaboration aims to expedite the development of advanced
Sarepta Therapeutics recently revealed financial results that indicate lower-than-expected sales for its flagship gene therapy product, Elevidys, designed to treat Duchenne muscular dystrophy (DMD). The sales figures for the second quarter fell short of Wall Street's projections, raising concerns
Autoimmune diseases, affecting millions of people worldwide, present a unique challenge where the body's immune system mistakenly attacks its tissues. Existing treatments primarily rely on immunosuppressants, which often come with severe side effects and don’t always offer a cure. Enter Candid
BlueRock Therapeutics, a cell therapy company under Bayer, has recently announced FDA clearance for its Investigational New Drug (IND) application for OpCT-001. This investigational induced pluripotent stem cell (iPSC)-derived therapy aims to treat primary photoreceptor diseases, which are a
Rentschler Biopharma has recently unveiled an innovative lentiviral vector (LVV) manufacturing toolbox at its advanced therapies site in Stevenage, United Kingdom, significantly enhancing its service offerings in the gene therapy sector. This strategic expansion complements their established
Arsenal Biosciences, commonly known as ArsenalBio, has achieved a remarkable milestone by securing $325 million in a Series C funding round. This significant financial boost arrives amid a challenging year for biotech investments, particularly in the cell and gene therapy sectors. The raised